Neptune, I'm currently only using the free service to post on iHub, I'm not currently a paid subscriber so I can't respond to private messages except during the one hour free period on Fridays.
To answer your question, I got a tip last year to check out Iovance by a friend who had been paying attention to it for several years. He said it was time to give it a more serious look as they were close to a possible approval. I did some due diligence, took a small position in May of last year, went through a few ups and downs with the various issues and delays, sold a few shares on some ups and bought a few shares again. Then it dropped down into the $3's and I wondered what I had gotten myself into. After that, I did a lot more due diligence and realized the reasons to own this stock were valid and started to build a much bigger position but at prices around $7 or higher, not when it was down in the $3's (dang).
I've now built a nice core position which I will hang onto for what should prove to be a very good ride upwards over the coming months and years if the company continues to execute on its plan. I will try to stay flexible enough in case I see any concerns, but so far the only real issues that we seem to be currently facing are overall market conditions and negative sector sentiment at this time.
Amtagvi approval cemented my reasons to stay long and to further build my position, I continue to stay long because Iovance's management team has proven itself through each of the steps they've taken in being prepared for each contingency and how they hit the ground running with the Amtagvi approval.
Iovance's bigger shareholders are known to be very successful in their investments when they take large positions in companies and I expect Iovance will be one more success on their lists. I don't mind following the leaders, and the individual that shared this lead with me also has a proven track record.
Finally, I tend to get a little impatient, but the advice I've gotten from others who know this arena and have proven themselves, including several posters on this board, remind me that earnings are the driving force for the stock price at this time along with additional TIL therapy approvals and new foreign markets for Iovance's products. I expected a bigger jump on Amtagvi approval, but the market will reward us handsomely on IOVA when revenues start hitting the bottom line. IOVA is still trading at a higher price than the pre-approval price, even following the secondary offering, but the sector has not been our friend over this past month and there's been no news to add to the story.
When Q2, Q3, Q4 and 2025 guidance are available for viewing, we should gain continual price support. If the market doesn't get ahead of the actual numbers, it should be a nice ride. If the biotech sector sentiment makes a turn to the positive again, that should also help the upside during those quiet news periods.
I would like to hear your story if you're willing to share. What brought you over to this board? Invited or did you just stumble onto this motley crew? How long have you been invested in IOVA (assuming you are)?
Good luck to you.
Badgerkid
